-
Novel serine protease dipeptidyl peptidase IV inhibitor: alogliptin.
Mini reviews in medicinal chemistry 20121101
-
Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results.
Journal of clinical pharmacology 20121001
-
Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study.
Diabetes, obesity & metabolism 20121001
-
Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice.
American journal of physiology. Renal physiology 20121001
-
Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition.
Cardiovascular research 20121001
-
Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors.
Bioorganic & medicinal chemistry 20121001
-
Linagliptin as add-on therapy for type 2 diabetes - an overview.
Drugs of today (Barcelona, Spain : 1998) 20121001
-
Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.
Clinical pharmacokinetics 20120801
-
Alogliptin as an initial therapy in patients with newly diagnosed, drug naïve type 2 diabetes: a randomized, control trial.
Endocrine 20120601
-
Novel pyrrolopyrimidine analogues as potent dipeptidyl peptidase IV inhibitors based on pharmacokinetic property-driven optimization.
European journal of medicinal chemistry 20120601
-
Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
The Journal of clinical endocrinology and metabolism 20120501
-
An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors.
Current diabetes reviews 20120501
-
DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
Diabetes & metabolism 20120401
-
Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study.
Diabetologia 20120401
-
Alogliptin benzoate for the treatment of type 2 diabetes.
Expert opinion on pharmacotherapy 20120301
-
Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus.
The Annals of pharmacotherapy 20120301
-
Pleiotropic effects of incretins.
Indian journal of endocrinology and metabolism 20120301
-
A review of gliptins in 2011.
Expert opinion on pharmacotherapy 20120101
-
DPP-4 inhibitors and lipids: systematic review and meta-analysis.
Advances in therapy 20120101
-
Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data.
Cardiovascular diabetology 20120101
-
Efficacy of various antidiabetic agents as add-on treatments to metformin in type 2 diabetes mellitus: systematic review and meta-analysis.
ISRN endocrinology 20120101
-
Pharmacological approaches to the management of type 2 diabetes in fasting adults during Ramadan.
Diabetes, metabolic syndrome and obesity : targets and therapy 20120101
-
Potent antiatherosclerotic effects of alogliptin in addition to its potent antidiabetic effects.
Diabetes, metabolic syndrome and obesity : targets and therapy 20120101
-
Recent advances in non-peptidomimetic dipeptidyl peptidase 4 inhibitors: medicinal chemistry and preclinical aspects.
Current medicinal chemistry 20120101
-
Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.
Diabetes, obesity & metabolism 20111201
-
Impact of diabetes on postinfarction heart failure and left ventricular remodeling.
Current heart failure reports 20111201
-
Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis.
Circulation 20111122
-
Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study.
Diabetes, obesity & metabolism 20111101
-
Tolerability of dipeptidyl peptidase-4 inhibitors: a review.
Clinical therapeutics 20111101
-
Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension.
Current medical research and opinion 20111101
-
Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials.
Current medical research and opinion 20111101
-
EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.
American heart journal 20111001
-
2-({6-[(3R)-3-amino-3-methylpiperidine-1-yl]-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-5H-pyrrolo[3,2-d]pyrimidine-5-yl}methyl)-4-fluorobenzonitrile (DSR-12727): a potent, orally active dipeptidyl peptidase IV inhibitor without mechanism-based inactivation of CYP3A.
Bioorganic & medicinal chemistry 20110915
-
Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study.
Current medical research and opinion 20110901
-
Linagliptin and newer DPP-4 inhibitors: newer uses and newer indications.
Recent patents on endocrine, metabolic & immune drug discovery 20110901
-
Emerging role of insulin with incretin therapies for management of type 2 diabetes.
Diabetes therapy : research, treatment and education of diabetes and related disorders 20110901
-
DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice.
Journal of cardiovascular pharmacology 20110801
-
[The expectation for DPP-4 inhibitors on future treatment of type 2 diabetes mellitus].
Nihon rinsho. Japanese journal of clinical medicine 20110801
-
Efficacy of sitagliptin when added to ongoing therapy in korean subjects with type 2 diabetes mellitus.
Diabetes & metabolism journal 20110801
-
Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: a brief overview.
Expert opinion on drug discovery 20110801
-
Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.
Drugs 20110730
-
Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.
Diabetes, obesity & metabolism 20110701
-
Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy.
Expert opinion on investigational drugs 20110601
-
An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.
Contemporary clinical trials 20110501
-
[Alogliptin].
Nihon rinsho. Japanese journal of clinical medicine 20110501
-
[A compounding agent of alogliptin and pioglitazone].
Nihon rinsho. Japanese journal of clinical medicine 20110501
-
[Emerging GLP-1 analogues and dipeptidyl peptidase 4(DPP-4) inhibitors].
Nihon rinsho. Japanese journal of clinical medicine 20110501
-
Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment.
Clinical therapeutics 20110501
-
Effects of chronic administration of alogliptin on the development of diabetes and β-cell function in high fat diet/streptozotocin diabetic mice.
Diabetes, obesity & metabolism 20110401
-
Alogliptin for the treatment of type 2 diabetes.
Drugs of today (Barcelona, Spain : 1998) 20110201
-
Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Hospital practice (1995) 20110201
-
Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV.
Journal of medicinal chemistry 20110127
-
Effect of alogliptin, pioglitazone and glargine on pancreatic β-cells in diabetic db/db mice.
Biochemical and biophysical research communications 20110107
-
The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes.
European journal of medicinal chemistry 20110101
-
[Pharmacological and clinical profile of alogliptin benzoate (NESINA®)].
Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20110101
-
Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways.
Vascular pharmacology 20110101
-
Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series.
Journal of medical case reports 20110101
-
Resveratrol increases glucose induced GLP-1 secretion in mice: a mechanism which contributes to the glycemic control.
PloS one 20110101
-
Effective therapy using voglibose for nonalcoholic steatohepatitis in a patient with insufficient dietary and exercise therapy: exploring other treatment possibilities.
Case reports in gastroenterology 20110101
-
From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy.
Experimental diabetes research 20110101
-
Treatment of streptozotocin-induced diabetic rats with alogliptin: effect on vascular and neural complications.
Experimental diabetes research 20110101
-
Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.
The open medicinal chemistry journal 20110101
-
Choosing a gliptin.
Indian journal of endocrinology and metabolism 20110101
-
Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy.
PloS one 20110101
-
A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
Cardiovascular diabetology 20110101
-
Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat).
Experimental diabetes research 20110101
-
DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes.
Atherosclerosis 20101201
-
Triple Combination Therapy Using Metformin, Thiazolidinedione, and a GLP-1 Analog or DPP-IV Inhibitor in Patients with Type 2 Diabetes Mellitus.
Korean diabetes journal 20101201
-
DPP-4 inhibitors: what may be the clinical differentiators?
Diabetes research and clinical practice 20101101
-
Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes.
Diabetes care 20101101
-
Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus.
Current diabetes reviews 20101101
-
Alogliptin: a review of its use in the management of type 2 diabetes mellitus.
Drugs 20101022
-
Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors.
The American journal of geriatric pharmacotherapy 20101001
-
Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
Clinical pharmacokinetics 20100901
-
Managing type 2 diabetes in the primary care setting: beyond glucocentricity.
The American journal of the medical sciences 20100801
-
Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
Diabetes, obesity & metabolism 20100801
-
Recommendations for management of diabetes during Ramadan: update 2010.
Diabetes care 20100801
-
The evolving place of incretin-based therapies in type 2 diabetes.
Pediatric nephrology (Berlin, Germany) 20100701
-
Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice.
Diabetes, obesity & metabolism 20100301
-
The physiologic role of incretin hormones: clinical applications.
The Journal of the American Osteopathic Association 20100301
-
Incretin concepts.
Diabetes care 20100201
-
Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects.
International journal of clinical pharmacology and therapeutics 20100101
-
The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review.
Diabetes technology & therapeutics 20100101
-
Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk.
Vascular health and risk management 20100101
-
Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat).
Mediators of inflammation 20100101
-
Synthesis of a novel analogue of DPP-4 inhibitor Alogliptin: Introduction of a spirocyclic moiety on the piperidine ring.
Beilstein journal of organic chemistry 20100101
-
Exenatide once weekly: clinical outcomes and patient satisfaction.
Patient preference and adherence 20100101
-
Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.
Vascular health and risk management 20100101
-
Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin.
Diabetes, metabolic syndrome and obesity : targets and therapy 20100101
-
New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin.
Diabetes, metabolic syndrome and obesity : targets and therapy 20100101
-
Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies.
Diabetes, metabolic syndrome and obesity : targets and therapy 20100101
-
Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy.
Drug, healthcare and patient safety 20100101
-
Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia.
Diabetes, obesity & metabolism 20091201
-
Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies.
Journal of the American Geriatrics Society 20091101
-
Incretin-based therapies: viewpoints on the way to consensus.
Diabetes care 20091101
-
Clinical pharmacology of alogliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of Type 2 diabetes.
Expert review of clinical pharmacology 20091101
-
Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants.
Journal of clinical pharmacology 20091001
-
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Current medical research and opinion 20091001
-
Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.
Clinical science (London, England : 1979) 20090928
-
The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone.
Diabetes care 20090901
-
Synthesis and evaluation of structurally constrained imidazolidin derivatives as potent dipeptidyl peptidase IV inhibitors.
European journal of medicinal chemistry 20090801
-
A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure.
Life sciences 20090717
-
Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.
British journal of pharmacology 20090601
-
Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.
The Journal of pharmacology and experimental therapeutics 20090501
-
Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes.
Bioorganic & medicinal chemistry 20090301
-
Diabetes treatment.
Diabetes care 20090301
-
DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy.
Advances in therapy 20090301
-
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy.
Diabetes, obesity & metabolism 20090201
-
Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Expert opinion on pharmacotherapy 20090201
-
The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice.
European journal of pharmacology 20090114
-
Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study.
International journal of clinical practice 20090101
-
Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice.
Postgraduate medicine 20090101
-
A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease.
Cardiovascular diabetology 20090101
-
Incretin-based therapies: new treatments for type 2 diabetes in the new millennium.
Therapeutics and clinical risk management 20090101
-
New therapeutic horizons: mapping the future of glycemic control with incretin-based therapy.
The Diabetes educator 20090101
-
Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Journal of the American Pharmacists Association : JAPhA 20090101
-
Efficacy and safety of incretin based therapies: clinical trial data.
Journal of the American Pharmacists Association : JAPhA 20090101
-
Alogliptin: a new addition to the class of DPP-4 inhibitors.
Diabetes, metabolic syndrome and obesity : targets and therapy 20090101
-
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study.
Diabetes care 20081201
-
Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes.
Expert opinion on emerging drugs 20081201
-
Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
European journal of pharmacology 20080728
-
Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.
European journal of pharmacology 20080707
-
(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors.
The Journal of pharmacology and experimental therapeutics 20080401
-
Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.
Current opinion in investigational drugs (London, England : 2000) 20080401
-
Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.
Clinical therapeutics 20080301
-
Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.
Clinical therapeutics 20080301
-
Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis.
BMC endocrine disorders 20080101
-
Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase IV.
Current topics in medicinal chemistry 20080101
-
Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.
Journal of medicinal chemistry 20070517
